SCHEMBL6921132

SCHEMBL6921132

COC(C)c1nc2cc(-c3ccccn3)ccc2c(=O)n1C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.46
TGFBR1 P36897 1/20 0.41
METAP2 P50579 2/20 0.38
DHODH Q02127 1/20 0.38
GABRG2 P18507 1/20 0.37
GABRB3 P28472 1/20 0.37
GABRA3 P34903 1/20 0.37
BRD4 O60885 2/20 0.36
FLT3 P36888 1/20 0.36
SYK P43405 1/20 0.36
AURKB Q96GD4 1/20 0.36
PRMT5 O14744 2/20 0.35
WDR77 Q9BQA1 1/20 0.35
RET P07949 1/20 0.35
RIPK1 Q13546 1/20 0.35
RIPK3 Q9Y572 1/20 0.35
PIK3CD O00329 1/20 0.34
PIK3CA P42336 1/20 0.34
PI4KA P42356 1/20 0.34
PIK3CG P48736 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6922265 0.88 CYP3A4 (0.46) CYP3A4TGFBR1METAP2DHODHGABRG2
SCHEMBL6922887 0.86 TGFBR1 (0.38) CYP3A4TGFBR1METAP2GABRG2GABRB3
SCHEMBL12059503 0.84 CYP3A4 (0.46) CYP3A4TGFBR1METAP2DHODHBRD4
SCHEMBL6920827 0.84 CYP3A4 (0.48) CYP3A4TGFBR1METAP2DHODHGABRG2
SCHEMBL12059125 0.83 CYP3A4 (0.45) CYP3A4TGFBR1METAP2DHODHBRD4
SCHEMBL12059153 0.81 BRD4 (0.39) CYP3A4GABRG2GABRB3GABRA3BRD4
SCHEMBL2053555 0.79 POLB (0.51)
SCHEMBL6922981 0.79 TNKS2 (0.40) CYP3A4TGFBR1
SCHEMBL6920540 0.79 CYP3A4 (0.47) CYP3A4TGFBR1METAP2DHODHGABRG2
SCHEMBL12059114 0.79 CYP3A4 (0.49) CYP3A4TGFBR1METAP2DHODHGABRG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110319380-A1 Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof SUNOVION PHARMACEUTICALS INC. (US) 2011-12-29 US disclosed
WO-2011075699-A2 COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC. (US) 2011-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110319380-A1 Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof GRM5, GRM2, GRM1 CYP3A4 4447/4885TGFBR1 3543/4885METAP2 2203/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.